Sifting through countless of stocks in the Biotechnology industry can be tedious, and sometimes two stocks are just too similar to judge which is the better investment. If you’re on the fence about investing in PTC Therapeutics, Inc., Arcus Biosciences or Inc. because you’re not sure how they measure up, it’s important to compare them on a few factors before making your decision.

Read on to learn how PTC Therapeutics, Inc., Arcus Biosciences and Inc. compare based on key financial metrics to determine which better meets your investment needs.

About PTC Therapeutics, Inc., Arcus Biosciences and Inc.

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to children and adults living with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington’s disease; and inflammation and ferroptosis platforms, including vatiquinone to treat Friedreich’s ataxia. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd., Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. The company has license and collaboration agreement with Novartis Pharmaceuticals Corporation to develop PTC518 Huntington's disease program. It markets Upstaza, a gene therapy with the brand name Kebilidi in the United States. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in Warren, New Jersey.

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company’s development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; and Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers. It also develops Quemliclustat, a small molecule inhibitor that targets the CD73 enzyme in the ATP-adenosine pathway, which is in phase 3 and phase 1/1b clinical trial for lung and pancreatic cancer; Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in phase 2 clinical trial for colorectal cancer; and Zimberelimab, an anti-PD-1 antibody. In addition, the company develops AB598, a CD39 antibody, which is in phase 1/1b clinical study for gastrointestinal cancer; and AB801, an AXL inhibitor, which is in Phase 1b clinical trial for lung cancer. It has clinical collaboration with AstraZeneca for the Phase 3 PACIFIC-8 trial evaluating domvanalimab and durvalumab in Stage 3 NSCLC and for a Phase 1/1b study evaluating casdatifan and volrustomig in IO-naive patients with ccRCC; and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is based in Hayward, California.

Latest Biotechnology and PTC Therapeutics, Inc., Arcus Biosciences, Inc. Stock News

As of December 5, 2025, PTC Therapeutics, Inc. had a $6.2 billion market capitalization, compared to the Biotechnology median of $217.8 million. PTC Therapeutics, Inc.’s stock is up 71.1% in 2025, down 10.2% in the previous five trading days and up 53.62% in the past year.

Currently, PTC Therapeutics, Inc.’s price-earnings ratio is 8.6. PTC Therapeutics, Inc.’s trailing 12-month revenue is $1.8 billion with a 42.3% net profit margin. Year-over-year quarterly sales growth most recently was 7.2%. Analysts expect adjusted earnings to reach $8.817 per share for the current fiscal year. PTC Therapeutics, Inc. does not currently pay a dividend.

As of December 5, 2025, Arcus Biosciences, Inc. had a $3.1 billion market cap, putting it in the 62nd percentile of all stocks. Arcus Biosciences, Inc.’s stock is up 70.9% in 2025, down 2.5% in the previous five trading days and up 54.81% in the past year.

Currently, Arcus Biosciences, Inc. does not have a price-earnings ratio. Arcus Biosciences, Inc.’s trailing 12-month revenue is $240.0 million with a -142.1% net profit margin. Year-over-year quarterly sales growth most recently was -45.8%. Analysts expect adjusted earnings to reach $-3.625 per share for the current fiscal year. Arcus Biosciences, Inc. does not currently pay a dividend.

How We Compare PTC Therapeutics, Inc., Arcus Biosciences and Inc. Stock Grades

Stock evaluation requires access to huge amounts of data and the knowledge and time to sift through it all, make sense of financial ratios, read income statements and analyze recent stock movements. AAII created A+ Investor, a robust data suite that condenses data research in an actionable and customizable way suitable for investors of all knowledge levels, to help investors streamline and work through such data.

AAII’s proprietary stock grades come with A+ Investor. These offer intuitive A‐F grades for each of five key investing factors: value, growth, momentum, earnings estimate revisions and quality. Here, we’ll take a closer look at PTC Therapeutics, Inc., Arcus Biosciences and Inc.’s stock grades to see how they measure up against one another.

Learn more about A+ Investor here!

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

PTC Therapeutics, Inc., Arcus Biosciences and Inc. Growth Grades

Company	Ticker	Growth
PTC Therapeutics, Inc.	PTCT	F
Arcus Biosciences, Inc.	RCUS	D

The foundation of growth investing is seeking out stocks of companies exhibiting strong, consistent and prolonged growth that is expected to continue into the future.

In order to compute the growth score and assign it a letter grade, the percentile ranks for each of three components‐consistency of annual sales growth, five-year sales growth rankings adjusted for extreme levels, and consistency of positive annual cash from operations‐must be determined. These three rank figures are added together, and the sum is ranked against the entire stock universe to arrive at a company’s Growth Score to create an equal distribution of grades.

The companies in the bottom 20% of the stock universe receive Growth Grades of F, considered to be very weak, while those in the top 20% receive A grades, which are considered very strong.

PTC Therapeutics, Inc. has a Growth Score of 20, which is Very Weak. Arcus Biosciences, Inc. has a Growth Score of 27, which is Weak.

The Growth Stock Winner: No Clear Winner

Neither PTC Therapeutics, Inc., Arcus Biosciences or Inc. has a high enough Growth Grade to be considered a “winner.” Investors who are considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolios. It’s important to look at a wide range of financial metrics in order to determine if PTC Therapeutics, Inc., Arcus Biosciences or Inc. is the better investment when it comes to sustainable growth.

PTC Therapeutics, Inc., Arcus Biosciences and Inc.’s Quality Grades

Company	Ticker	Quality
PTC Therapeutics, Inc.	PTCT	A
Arcus Biosciences, Inc.	RCUS	F

Like the Value Grade, AAII’s A+ Investor Quality Grade comes from the percentile rank of key metrics. Specifically, the Quality Score is the percentile rank of the average of the percentile ranks of return on assets (ROA), return on invested capital (ROIC), gross profit relative to assets, buyback yield, change in total liabilities to assets, accruals, Z double prime bankruptcy risk (Z) score and the F-Score.

The score is variable, meaning it can consider all eight measures or, should any of the eight measures not be valid, the remaining measures that are valid. To be assigned a Quality Score, stocks must have a valid (non-null) measure and corresponding ranking for at least four of the eight quality measures.

The Quality Score is used to assess the underlying “quality” of a particular stock. A higher-quality stock possesses traits associated with upside potential and reduced downside risk. Backtesting of the Quality Grade shows that stocks with higher grades, on average, outperformed stocks with lower grades over the period of 1998 through 2019.

Stocks receive better grades (higher scores) for having higher scores for the quality subcomponents and worse grades (lower scores) for lower scores for the subcomponents.

PTC Therapeutics, Inc. has a Quality Score of 88, which is Very Strong. Arcus Biosciences, Inc. has a Quality Score of 6, which is Very Weak.

The Quality Grade Winner: PTC Therapeutics, Inc.

As you can clearly see from the Quality Grade breakdown above, PTC Therapeutics, Inc. has a better overall quality grade than Arcus Biosciences, Inc.. For investors who are looking for companies with higher quality than others in the same industry, PTC Therapeutics, Inc. could be a good stock to add to their portfolios. However, it’s important for investors to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

PTC Therapeutics, Inc., Arcus Biosciences and Inc.’s Estimate Revisions Grades

Company	Ticker	Earnings Estimate
PTC Therapeutics, Inc.	PTCT	B
Arcus Biosciences, Inc.	RCUS	B

Earnings estimate revisions scores consider the magnitude of a company’s earnings surprise in its last two reported fiscal quarters. Often, positive surprises beget further positive surprises‐or at least continued sales growth (the exact opposite is generally true, too).

Estimate revisions offer an indication of what analysts are thinking about the short-term prospects of a firm. Estimate revisions are based on the statistical significance of a firm’s last two quarterly earnings surprises and the percentage change in its consensus estimate for the current fiscal year over the past month and past three months.

PTC Therapeutics, Inc. has a Earnings Estimate Score of 80, which is Positive. Arcus Biosciences, Inc. has a Earnings Estimate Score of 66, which is Positive.

The Earnings Estimate Revisions Grade Winner: It’s a Tie!

Looking at the Earnings Estimate Revisions Grade breakdown above, both PTC Therapeutics, Inc., Arcus Biosciences and Inc. have a grade of B. For those focusing solely on a company’s estimate revisions, other financial metrics will need to be evaluated to determine whether PTC Therapeutics, Inc., Arcus Biosciences or Inc. is a better fit.

Other PTC Therapeutics, Inc., Arcus Biosciences and Inc. Grades

In addition to Growth, Quality and Estimate Revisions, A+ Investor also provides grades for Value and Momentum.

Momentum grades help uncover stocks experiencing anomalously high rates of return; research finds that stocks with high relative levels of momentum tend to outperform, whereas those with low levels of momentum tend to continue underperforming.

Successful stock investing involves buying low and selling high, so stock valuation is an important consideration for stock selection. Buying stocks that are going to go up typically means buying stocks that are undervalued in the first place, although momentum investors may argue that point.

These 2 key factors, when combined with the above, provide a holistic view into a particular stock. Further, by joining A+ Investor you can see whether PTC Therapeutics, Inc., Arcus Biosciences and Inc. pass any of our 60+ stock screens that have outperformed the market since their creation.

So, Which Is the Better Investment, PTC Therapeutics, Inc., Arcus Biosciences or Inc. Stock?

Overall, PTC Therapeutics, Inc. stock has a Growth Score of 20, Estimate Revisions Score of 80 and Quality Score of 88.

Arcus Biosciences, Inc. stock has a Growth Score of 27, Estimate Revisions Score of 66 and Quality Score of 6.

Comparing PTC Therapeutics, Inc., Arcus Biosciences and Inc.’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. You’ll also want to look at your portfolio’s asset allocation as well as your risk tolerance and financial goals to see if either of these stocks would make a good fit for you. AAII can help you figure out which investments align with your individual needs and preferences.

Investors are encouraged to do their own due diligence and research. In this way, individuals can effectively become managers of their own assets‐without having to rely on others for financial independence. You can count on AAII for timeless articles on financial planning and stock-picking, unbiased research and actionable analysis.

A+ Investor adds to our qualitative teaching with a powerful data suite to help you whittle down investment choices to find stocks, exchange-traded funds (ETFs) or mutual funds that meet your needs.

AAII Disclaimer

We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown, because past, hypothetical or simulated performance is not necessarily indicative of future results. Before making an investment decision, you should consider your circumstances and whether the information on our content is applicable to your situation. This information was prepared in good faith, and we accept no liability for any errors or omissions. The full disclaimer can be read here.